论文部分内容阅读
应用Ames试验、体外染色体畸变试验、微核试验和显性致死试验对磷酸羟基哌喹(HPQP)的致突性进行了实验研究。结果表明,HPQP对TA97a、TA98、TA100和TA102无致突性。各剂量组的染色体畸变率均低于3％。以1/2、1/10和1/25LD_(50)的剂量诱发小鼠骨髓多染红细胞的微核率分别为5.7±2.55、5.3±1.70和4.3±2.11,与阴性对照无区别。根据活胎率,平均早死数等指标表明HPQP无显性致死突变。综合本组试验结果,可认为HPQP未显示有致突性。
The Ames test, in vitro chromosomal aberration test, micronucleus test and dominant lethal test were used to study the mutagenicity of HPQP. The results showed that HPQP had no mutagenicity on TA97a, TA98, TA100 and TA102. Chromosome aberration rates were lower than 3% for each dose group. The micronuclei rates of mouse erythrocytes were 5.7 ± 2.55, 5.3 ± 1.70 and 4.3 ± 2.11, respectively, which were not significantly different from those of the negative control. According to the live fetus rate, the average early death rate and other indicators show no significant fatal HPQP mutation. Based on the results of this group of experiments, HPQP can be considered did not show mutagenicity.